
Last 4 earnings calls · through Q2 FY2026
The bull case is that years of company-funded research have turned into defense hardware programs that customers are now ordering in quantity rather than studying.
Buying an energy engineering firm adds scale in grid design, a market where utilities spend heavily and where the company already sells design software.
Strong cash conversion pays for added production capacity and still leaves room for acquisitions, dividends and share repurchases without straining the balance sheet.
The bear case is that the veterans exam franchise, the company's most profitable business, is being repriced while a fourth vendor takes share of the work.
Profitability is guided below last year as one-time benefits fade, and the energy acquisition added debt that reduces room to buy back stock.
Government customers are buying commercial software directly and doing more integration themselves, which erodes the role the company has played in large programs.
In short: Defense orders and the energy acquisition are growing, while the veterans exam business is shrinking.
Defense booked 2.2 times its quarterly revenue in new work, so the segment enters the second half with orders already in hand rather than relying on awards still to be decided.
Entrust closed two months after announcement and management raised 2026 revenue guidance by $500 million mainly because of it, so the deal is adding sales faster than planned.
Health is the company's second-largest segment and its exam work is the highest-margin business, so lost volume there removes profit, not just sales.
Management said in May that exam volumes were staying high despite the fourth vendor; in August it said the customer is pausing incentive payments and Health revenue contracted.
In short: Cash generation is strong, while margins are guided down and debt rose to fund the energy deal.
Leidos produced $2.2 billion of free cash flow over the last twelve months, or 12.3% of revenue, so reported profit converts into cash that funds production investment and returns.
In February management said it would triple capital spending; it now expects about $250 million instead of $350 million and raised implied free cash flow by roughly $150 million.
Operating margin came in at 11.3%, down 2.1 points from a year earlier, so profit growth is coming from sales volume and acquisitions rather than from the underlying margin.
Net debt rose to $5.3 billion from $4.2 billion a year earlier after the all-cash energy deal, and management says acquisition prices are high, so share repurchases compete for the same capital.
In short: Leidos holds defense production programs, but in-sourcing and a recompete threaten its services work.
The $2.2 billion award converts years of company-funded radar research into a five-year production contract for base defense against aircraft and cruise missiles.
Management described defense tech as focused on space and maritime; it now counts munitions and counter-drone systems as separate production engines with their own order pipelines.
A fourth vendor is taking share and the government has not issued the RFP, so the largest profit pool in Health will be repriced under terms the company cannot yet see.
The Defense Health Agency plans to buy commercial software directly and may integrate it itself, and management says in-sourcing interest is spreading, which shrinks the integrator role Leidos has played.